Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Lung Cancer

  Free Subscription


Articles published in Anticancer Res

Retrieve available abstracts of 162 articles:
HTML format
Text format



Single Articles


    April 2017
  1. TSOUKALAS N, Aravantinou-Fatorou E, Tolia M, Giaginis C, et al
    Epithelial-Mesenchymal Transition in Non Small-cell Lung Cancer.
    Anticancer Res. 2017;37:1773-1778.
    PubMed     Text format     Abstract available


  2. OKAMOTO T, Kohno M, Ito K, Takada K, et al
    Clinical Significance of DNA Damage Response Factors and Chromosomal Instability in Primary Lung Adenocarcinoma.
    Anticancer Res. 2017;37:1729-1735.
    PubMed     Text format     Abstract available


    March 2017
  3. KASMANN L, Bolm L, Janssen S, Rades D, et al
    Prognostic Factors and Treatment of Early-stage Small-cell Lung Cancer.
    Anticancer Res. 2017;37:1535-1537.
    PubMed     Text format     Abstract available


  4. YOH K, Goto Y, Naito Y, Kishi K, et al
    Impact of Maintenance Therapy for Patients with Non-small Cell Lung Cancer in a Real-world Setting.
    Anticancer Res. 2017;37:1507-1513.
    PubMed     Text format     Abstract available


  5. TOYOKAWA G, Takada K, Okamoto T, Kozuma Y, et al
    Elevated Metabolic Activity on 18F-FDG PET/CT Is Associated with the Expression of EZH2 in Non-small Cell Lung Cancer.
    Anticancer Res. 2017;37:1393-1401.
    PubMed     Text format     Abstract available


  6. WINDRICHOVA J, Fuchsova R, Kucera R, Topolcan O, et al
    MIC1/GDF15 as a Bone Metastatic Disease Biomarker.
    Anticancer Res. 2017;37:1501-1505.
    PubMed     Text format     Abstract available


  7. TAGAWA T, Ito K, Fukuzawa K, Okamoto T, et al
    Surgical Resection for Pulmonary Metastasis from Pancreatic and Biliary Tract Cancer.
    Anticancer Res. 2017;37:1413-1416.
    PubMed     Text format     Abstract available


  8. BATTOLLA E, Canessa PA, Ferro P, Franceschini MC, et al
    Comparison of the Diagnostic Performance of Fibulin-3 and Mesothelin in Patients with Pleural Effusions from Malignant Mesothelioma.
    Anticancer Res. 2017;37:1387-1391.
    PubMed     Text format     Abstract available


    February 2017
  9. SONE K, Oguri T, Nakao M, Kagawa Y, et al
    CYFRA 21-1 as a Predictive Marker for Non-small Cell Lung Cancer Treated with Pemetrexed-based Chemotherapy.
    Anticancer Res. 2017;37:935-939.
    PubMed     Text format     Abstract available


  10. YAMASAKI M, Murakami I, Nakano K, Doi M, et al
    Carboplatin plus Weekly Paclitaxel Combined with Bevacizumab as First-line Treatment for Non-small Cell Lung Cancer.
    Anticancer Res. 2017;37:923-928.
    PubMed     Text format     Abstract available


  11. TOYOKAWA G, Kozuma Y, Matsubara T, Haratake N, et al
    Radiological Features of the Surgically Resected Small-sized Small-cell Lung Cancer on Computed Tomography.
    Anticancer Res. 2017;37:877-881.
    PubMed     Text format     Abstract available


  12. TAKEDA K, Yamasaki A, Igishi T, Kawasaki Y, et al
    Frequency of Epidermal Growth Factor Receptor Mutation in Smokers with Lung Cancer Without Pulmonary Emphysema.
    Anticancer Res. 2017;37:765-771.
    PubMed     Text format     Abstract available


  13. SHOJI F, Haratake N, Akamine T, Takamori S, et al
    The Preoperative Controlling Nutritional Status Score Predicts Survival After Curative Surgery in Patients with Pathological Stage I Non-small Cell Lung Cancer.
    Anticancer Res. 2017;37:741-747.
    PubMed     Text format     Abstract available


  14. ISHIKURA N, Yanagisawa M, Noguchi-Sasaki M, Iwai T, et al
    Importance of Bevacizumab Maintenance Following Combination Chemotherapy in Human Non-small Cell Lung Cancer Xenograft Models.
    Anticancer Res. 2017;37:623-629.
    PubMed     Text format     Abstract available


  15. SIRIMANGKALAKITTI N, Chamni S, Suwanborirux K, Chanvorachote P, et al
    Renieramycin M Attenuates Cancer Stem Cell-like Phenotypes in H460 Lung Cancer Cells.
    Anticancer Res. 2017;37:615-621.
    PubMed     Text format     Abstract available


  16. RAFEI H, El-Bahesh E, Finianos A, Nassereddine S, et al
    Immune-based Therapies for Non-small Cell Lung Cancer.
    Anticancer Res. 2017;37:377-387.
    PubMed     Text format     Abstract available


  17. TANDBERG DJ, Holt T, Kelsey CR
    Plasma Metabolites and Risk of Radiation-induced Esophagitis: A Secondary Analysis from a Prospective Study.
    Anticancer Res. 2017;37:719-725.
    PubMed     Text format     Abstract available


  18. LIM YS, Cha W, Park MW, Jeong WJ, et al
    HIF1alpha in Tumorigenesis of Adenoid Cystic Carcinoma.
    Anticancer Res. 2017;37:599-606.
    PubMed     Text format     Abstract available


    January 2017
  19. CHUDASAMA D, Barr J, Beeson J, Beddows E, et al
    Detection of Circulating Tumour Cells and Survival of Patients with Non-small Cell Lung Cancer.
    Anticancer Res. 2017;37:169-173.
    PubMed     Text format     Abstract available


  20. SUZAWA K, Shien K, Peng H, Sakaguchi M, et al
    Distant Bystander Effect of REIC/DKK3 Gene Therapy Through Immune System Stimulation in Thoracic Malignancies.
    Anticancer Res. 2017;37:301-307.
    PubMed     Text format     Abstract available


  21. FUJIYOSHI K, Yamamoto G, Takenoya T, Takahashi A, et al
    Metastatic Pattern of Stage IV Colorectal Cancer with High-Frequency Microsatellite Instability as a Prognostic Factor.
    Anticancer Res. 2017;37:239-247.
    PubMed     Text format     Abstract available


  22. YURUGI Y, Wakahara M, Matsuoka Y, Sakabe T, et al
    Podoplanin Expression in Cancer-associated Fibroblasts Predicts Poor Prognosis in Patients with Squamous Cell Carcinoma of the Lung.
    Anticancer Res. 2017;37:207-213.
    PubMed     Text format     Abstract available


  23. PASQUALETTI F, Montrone S, Vivaldi C, Zani M, et al
    Stereotactic Body Radiotherapy in Patients with Lung Oligometastases from Colorectal Cancer.
    Anticancer Res. 2017;37:315-319.
    PubMed     Text format     Abstract available


  24. YANO S, Takehara K, Kishimoto H, Tazawa H, et al
    Comparison of Tumor Recurrence After Resection of Highly- and Poorly-Metastatic Triple-negative Breast Cancer in Orthotopic Nude-Mouse Models.
    Anticancer Res. 2017;37:57-60.
    PubMed     Text format     Abstract available


    December 2016
  25. ISLA D, Felip E, Vinolas N, Provencio M, et al
    Lung Cancer in Women with a Family History of Cancer: The Spanish Female-specific Database WORLD07.
    Anticancer Res. 2016;36:6647-6653.
    PubMed     Text format     Abstract available


  26. KAIRA K, Higuchi T, Sunaga N, Arisaka Y, et al
    Usefulness of 18F-alpha-Methyltyrosine PET for Therapeutic Monitoring of Patients with Advanced Lung Cancer.
    Anticancer Res. 2016;36:6481-6490.
    PubMed     Text format     Abstract available


  27. PINKHIEN T, Maiuthed A, Chamni S, Suwanborirux K, et al
    Bishydroquinone Renieramycin M Induces Apoptosis of Human Lung Cancer Cells Through a Mitochondria-dependent Pathway.
    Anticancer Res. 2016;36:6327-6333.
    PubMed     Text format     Abstract available


  28. YOSHIDA T, Okamoto T, Yano T, Takada K, et al
    Molecular Factors Associated with Pemetrexed Sensitivity According to Histological Type in Non-small Cell Lung Cancer.
    Anticancer Res. 2016;36:6319-6326.
    PubMed     Text format     Abstract available


  29. GRIDELLI C, Chella A, Valmadre G, Allegrini G, et al
    Second-line Erlotinib or Intermittent Erlotinib plus Docetaxel in Male Ex-smokers with Squamous NSCLC: The TALISMAN Randomized Trial.
    Anticancer Res. 2016;36:6535-6540.
    PubMed     Text format     Abstract available


  30. CHECK JH, Check D, Wilson C, Lofberg P, et al
    Long-term High-quality Survival with Single-agent Mifepristone Treatment Despite Advanced Cancer.
    Anticancer Res. 2016;36:6511-6513.
    PubMed     Text format     Abstract available


  31. SUNDARAM S, Yan L
    High-fat Diet Enhances Mammary Tumorigenesis and Pulmonary Metastasis and Alters Inflammatory and Angiogenic Profiles in MMTV-PyMT Mice.
    Anticancer Res. 2016;36:6279-6287.
    PubMed     Text format     Abstract available


  32. OKAZAKI I, Ishikawa S, Ando W, Sohara Y, et al
    Lung Adenocarcinoma in Never Smokers: Problems of Primary Prevention from Aspects of Susceptible Genes and Carcinogens.
    Anticancer Res. 2016;36:6207-6224.
    PubMed     Text format     Abstract available


    November 2016
  33. HSIA TC, Yu CC, Hsiao YT, Wu SH, et al
    Cantharidin Impairs Cell Migration and Invasion of Human Lung Cancer NCI-H460 Cells via UPA and MAPK Signaling Pathways.
    Anticancer Res. 2016;36:5989-5997.
    PubMed     Text format     Abstract available


  34. YASUKAWA M, Nakazawa T, Kawaguchi T, Kawai N, et al
    Minodronic Acid in Combination with gammadeltaT Cells Induces Apoptosis of Non-small Cell Lung Carcinoma Cell Lines.
    Anticancer Res. 2016;36:5883-5886.
    PubMed     Text format     Abstract available


  35. CHANVORACHOTE P, Chamni S, Ninsontia C, Phiboonchaiyanan PP, et al
    Potential Anti-metastasis Natural Compounds for Lung Cancer.
    Anticancer Res. 2016;36:5707-5717.
    PubMed     Text format     Abstract available


  36. WATARAI H, Okada M, Kuramoto K, Takeda H, et al
    Impact of H3K27 Demethylase Inhibitor GSKJ4 on NSCLC Cells Alone and in Combination with Metformin.
    Anticancer Res. 2016;36:6083-6092.
    PubMed     Text format     Abstract available


  37. YE X, Zhou Q, Matsumoto Y, Moriyama M, et al
    Inhibition of Glutaminolysis Inhibits Cell Growth via Down-regulating Mtorc1 Signaling in Lung Squamous Cell Carcinoma.
    Anticancer Res. 2016;36:6021-6029.
    PubMed     Text format     Abstract available


  38. AMBROSIO R, Ombra MN, Gridelli C, Picariello G, et al
    Isoflavone Extracts Enhance the Effect of Epidermal Growth Factor Receptor Inhibitors in NSCLC Cell Lines.
    Anticancer Res. 2016;36:5827-5833.
    PubMed     Text format     Abstract available


    October 2016
  39. KARZIJN R, Alberts L, Kelder JC, Hofman FN, et al
    Post-treatment Surveillance for Stage I and II Non-small Cell Lung Cancer: Impact on Clinical Outcome.
    Anticancer Res. 2016;36:5413-5418.
    PubMed     Text format     Abstract available


  40. KOYI H, Hillerdal G, Kolbeck KG, Brodin D, et al
    Non-small Cell Lung Cancer (NSCLC) in Octogenarians in Clinical Practice.
    Anticancer Res. 2016;36:5397-5402.
    PubMed     Text format     Abstract available


  41. SHAVERDIAN N, Wang J, Levin-Epstein R, Schaue D, et al
    Pro-inflammatory State Portends Poor Outcomes with Stereotactic Radiosurgery for Brain Metastases.
    Anticancer Res. 2016;36:5333-5337.
    PubMed     Text format     Abstract available


  42. MAEBAYASHI T, Ishibashi N, Aizawa T, Sakaguchi M, et al
    Radiation Pneumonitis Changes over Time after Stereotactic Body Radiation Therapy for Lung Tumors: Post-treatment Cavity (Sunny-side-up Egg-like) Changes.
    Anticancer Res. 2016;36:5563-5570.
    PubMed     Text format     Abstract available


    September 2016
  43. INOMATA M, Shimokawa K, Tokui K, Taka C, et al
    Appetite Loss as an Adverse Effect During Treatment with EGFR-TKIs in Elderly Patients with Non-small Cell Lung Cancer.
    Anticancer Res. 2016;36:4951-4.
    PubMed     Text format     Abstract available


  44. SCHMID S, LE UT, Haager B, Mayer O, et al
    Local Concentrations of CC-Chemokine-Ligand 18 Correlate with Tumor Size in Non-small Cell Lung Cancer and Are Elevated in Lymph Node-positive Disease.
    Anticancer Res. 2016;36:4667-71.
    PubMed     Text format     Abstract available


  45. MATSUOKA Y, Yurugi Y, Takagi Y, Wakahara M, et al
    Prognostic Significance of Solid and Micropapillary Components in Invasive Lung Adenocarcinomas Measuring </=3 cm.
    Anticancer Res. 2016;36:4923-30.
    PubMed     Text format     Abstract available


  46. TOYOKAWA G, Taguchi K, Edagawa M, Shimamatsu S, et al
    The Prognostic Impact of Jumonji Domain-containing 2B in Patients with Resected Lung Adenocarcinoma.
    Anticancer Res. 2016;36:4841-6.
    PubMed     Text format     Abstract available


  47. VAN DER MEER FS, Schramel FM, VAN Vulpen M, El Sharouni SY, et al
    Feasibility of Concomitant Chemoradiotherapy in Daily Practice for Patients with NSCLC Stage III.
    Anticancer Res. 2016;36:4673-6.
    PubMed     Text format     Abstract available


    August 2016
  48. TOYOKAWA G, Takada K, Haratake N, Takamori S, et al
    Favorable Disease-free Survival Associated with Programmed Death Ligand 1 Expression in Patients with Surgically Resected Small-cell Lung Cancer.
    Anticancer Res. 2016;36:4329-36.
    PubMed     Text format     Abstract available


  49. OOI H, Chen CY, Hsiao YC, Huang WS, et al
    Fluorodeoxyglucose Uptake in Advanced Non-small Cell Lung Cancer With and Without Pulmonary Lymphangitic Carcinomatosis.
    Anticancer Res. 2016;36:4313-20.
    PubMed     Text format     Abstract available


  50. DAVIES RS, Nelmes DJ, Butler R, Lester JF, et al
    Non-small Cell Lung Cancer in South Wales: Are Exon 19 Deletions and L858R Different?
    Anticancer Res. 2016;36:4267-71.
    PubMed     Text format     Abstract available


  51. KASMANN L, Janssen S, Rades D
    Karnofsky Performance Score, Radiation Dose and Nodal Status Predict Survival of Elderly Patients Irradiated for Limited-disease Small-cell Lung Cancer.
    Anticancer Res. 2016;36:4177-80.
    PubMed     Text format     Abstract available


  52. SILVONIEMI M, Vasankari T, Loyttyniemi E, Valtonen M, et al
    Symptom Assessment for Patients with Non-small Cell Lung Cancer Scheduled for Chemotherapy.
    Anticancer Res. 2016;36:4123-8.
    PubMed     Text format     Abstract available



  53. Advances in Respiratory Cancerogenesis.
    Anticancer Res. 2016;36:4376.
    PubMed     Text format    


  54. URAMOTO H, Nakajima Y, Kinoshita H, Akiyama H, et al
    Equivalent Outcome of Patients with Locally Advanced NSCLC Treated with Salvage Surgery Compared to Induction Chemotherapy Followed by Surgical Resection.
    Anticancer Res. 2016;36:4243-7.
    PubMed     Text format     Abstract available


  55. MAYS AC, Feng X, Browne JD, Sullivan CA, et al
    Chemokine and Chemokine Receptor Profiles in Metastatic Salivary Adenoid Cystic Carcinoma.
    Anticancer Res. 2016;36:4013-8.
    PubMed     Text format     Abstract available


  56. TOME Y, Yano S, Sugimoto N, Mii S, et al
    Use of alphav Integrin Linked to Green Fluorescent Protein in Osteosarcoma Cells and Confocal Microscopy to Image Molecular Dynamics During Lung Metastasis in Nude Mice.
    Anticancer Res. 2016;36:3811-6.
    PubMed     Text format     Abstract available


    July 2016
  57. INUI T, Amitani H, Kubo K, Kuchiike D, et al
    Case Report: A Non-small Cell Lung Cancer Patient Treated with GcMAF, Sonodynamic Therapy and Tumor Treating Fields.
    Anticancer Res. 2016;36:3767-70.
    PubMed     Text format     Abstract available


  58. YAMASHITA K, Hasegawa H, Fujita M, Nishi M, et al
    Host CD40 Is Essential for DCG Treatment Against Metastatic Lung Cancer.
    Anticancer Res. 2016;36:3659-65.
    PubMed     Text format     Abstract available


  59. KASMANN L, Janssen S, Rades D
    Prognostic Factors Including the Expression of Thyroid Transcription Factor 1 (TTF1) in Patients Irradiated for Limited-disease Small Cell Lung Cancer.
    Anticancer Res. 2016;36:3499-503.
    PubMed     Text format     Abstract available


  60. TAKADA K, Toyokawa G, Okamoto T, Akamine T, et al
    An Immunohistochemical Analysis of PD-L1 Protein Expression in Surgically Resected Small Cell Lung Cancer Using Different Antibodies and Criteria.
    Anticancer Res. 2016;36:3409-12.
    PubMed     Text format     Abstract available


  61. HOLZER TR, Fulford AD, Reising LO, Nedderman DM, et al
    Profiling of Vascular Endothelial Growth Factor Receptor Heterogeneity Identifies Protein Expression-defined Subclasses of Human Non-small Cell Lung Carcinoma.
    Anticancer Res. 2016;36:3277-88.
    PubMed     Text format     Abstract available


  62. OISHI S, Kudaka W, Toita T, Ariga T, et al
    Prognostic Factors and Treatment Outcome for Patients with Stage IVB Cervical Cancer.
    Anticancer Res. 2016;36:3471-5.
    PubMed     Text format     Abstract available


  63. MATSUI T, Nagata N, Hirata K, Okazaki S, et al
    Bi-weekly Capecitabine-Oxaliplatin (XELOX) plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer -The PHOENiX Trial.
    Anticancer Res. 2016;36:3437-43.
    PubMed     Text format     Abstract available


    June 2016
  64. TAMIYA M, Tamiya A, Yasue T, Nakao K, et al
    Vascular Endothelial Growth Factor in Plasma and Pleural Effusion Is a Biomarker for Outcome After Bevacizumab plus Carboplatin-Paclitaxel Treatment for Non-small Cell Lung Cancer with Malignant Pleural Effusion.
    Anticancer Res. 2016;36:2939-44.
    PubMed     Text format     Abstract available


  65. YAMADA K, Azuma K, Takeshita M, Uchino J, et al
    Phase II Trial of Erlotinib in Elderly Patients with Previously Treated Non-small Cell Lung Cancer: Results of the Lung Oncology Group in Kyushu (LOGiK-0802).
    Anticancer Res. 2016;36:2881-7.
    PubMed     Text format     Abstract available


  66. OKAMOTO T, Kitahara H, Shimamatsu S, Katsura M, et al
    Prognostic Impact of EGFR Driver Mutations on Postoperative Disease Recurrence in Lung Adenocarcinoma.
    Anticancer Res. 2016;36:3057-63.
    PubMed     Text format     Abstract available


    May 2016
  67. URAMOTO H, Iijima Y, Nakajima Y, Kinoshita H, et al
    Accurate Diagnosis of Aortic Invasion in Patients with Lung Cancer.
    Anticancer Res. 2016;36:2391-5.
    PubMed     Text format     Abstract available


  68. URAMOTO H, Nakajima Y, Kinoshita H
    Is the Isolated Pericardial Fat Pad Sufficient to Cover the Bronchial Stump and Separate the Pulmonary Artery in Order to Prevent Bronchopleural Fistula in Patients with Lung Cancer?
    Anticancer Res. 2016;36:2385-9.
    PubMed     Text format     Abstract available


  69. NICOS M, Krawczyk P, Powrozek T, Szudy P, et al
    PIK3CA Mutations Detected in Patients with Central Nervous System Metastases of Non-small Cell Lung Cancer.
    Anticancer Res. 2016;36:2243-9.
    PubMed     Text format     Abstract available


  70. SU JM, Hsu YY, Lin P, Chang H, et al
    Nuclear Accumulation of Heat-shock Protein 90 Is Associated with Poor Survival and Metastasis in Patients with Non-small Cell Lung Cancer.
    Anticancer Res. 2016;36:2197-203.
    PubMed     Text format     Abstract available


  71. ROCCO G, Petitti T, Martucci N, Piccirillo MC, et al
    Survival After Surgical Treatment of Lung Cancer Arising in the Population Exposed to Illegal Dumping of Toxic Waste in the Land of Fires ('Terra dei Fuochi') of Southern Italy.
    Anticancer Res. 2016;36:2119-24.
    PubMed     Text format     Abstract available


  72. FIALA O, Pesek M, Finek J, Topolcan O, et al
    Change in Serum Lactate Dehydrogenase Is Associated with Outcome of Patients with Advanced-stage NSCLC Treated with Erlotinib.
    Anticancer Res. 2016;36:2459-65.
    PubMed     Text format     Abstract available


  73. UGURLUER G, Chang K, Gamez ME, Arnett AL, et al
    Genome-based Mutational Analysis by Next Generation Sequencing in Patients with Malignant Pleural and Peritoneal Mesothelioma.
    Anticancer Res. 2016;36:2331-8.
    PubMed     Text format     Abstract available


    April 2016

  74. Lung Cancer and Personalized Medicine: Novel Therapies and Clinical Management.
    Anticancer Res. 2016;36:2049.
    PubMed     Text format    



  75. Lung Cancer and Personalized Medicine. Current Knowledge and Therapies.
    Anticancer Res. 2016;36:2049.
    PubMed     Text format    


  76. JANSSEN S, Kaesmann L, Schild SE, Rades D, et al
    Impact of the Radiation Dose and Completion of Palliative Radiotherapy on Survival in Patients Treated for Locally Advanced Lung Cancer.
    Anticancer Res. 2016;36:1825-8.
    PubMed     Text format     Abstract available


  77. KIMURA T, Taniguchi H, Watanabe N, Saka H, et al
    Phase II Study of Carboplatin and Pemetrexed in Advanced EGFR-wild-type Non-squamous Non-small Cell Lung Cancer: The Central Japan Lung Study Group Trial 0906.
    Anticancer Res. 2016;36:1767-71.
    PubMed     Text format     Abstract available


  78. KESHTGARPOUR M, Tan WS, Zwanziger J, Awadalla S, et al
    Prognostic Value of Serum Proteomic Test and Comorbidity Index in Diversified Population with Lung Cancer.
    Anticancer Res. 2016;36:1759-65.
    PubMed     Text format     Abstract available


  79. SIRIMANGKALAKITTI N, Chamni S, Suwanborirux K, Chanvorachote P, et al
    Renieramycin M Sensitizes Anoikis-resistant H460 Lung Cancer Cells to Anoikis.
    Anticancer Res. 2016;36:1665-71.
    PubMed     Text format     Abstract available


  80. BAZIN MA, Rousseau B, Marhadour S, Tomasoni C, et al
    Discovery of Novel (Imidazo[1,2-a]pyrazin-6-yl)ureas as Antiproliferative Agents Targeting P53 in Non-small Cell Lung Cancer Cell Lines.
    Anticancer Res. 2016;36:1621-30.
    PubMed     Text format     Abstract available


  81. TADOKORO A, Kanaji N, Liu D, Yokomise H, et al
    Vimentin Regulates Invasiveness and Is a Poor Prognostic Marker in Non-small Cell Lung Cancer.
    Anticancer Res. 2016;36:1545-51.
    PubMed     Text format     Abstract available


  82. GEBAUER F, Wicklein D, Tachezy M, Grob T, et al
    Establishment and Characterization of a Pair of Patient-derived Human Non-small Cell Lung Cancer Cell Lines from a Primary Tumor and Corresponding Lymph Node Metastasis.
    Anticancer Res. 2016;36:1507-18.
    PubMed     Text format     Abstract available


  83. WINDRICHOVA J, Fuchsova R, Kucera R, Topolcan O, et al
    Testing of a Novel Cancer Metastatic Multiplex Panel for the Detection of Bone-metastatic Disease - a Pilot Study.
    Anticancer Res. 2016;36:1973-8.
    PubMed     Text format     Abstract available


  84. NISMAN B, Appelbaum L, Yutkin V, Nechushtan H, et al
    Serum Thymidine Kinase 1 Activity Following Nephrectomy for Renal Cell Carcinoma and Radiofrequency Ablation of Metastases to Lung and Liver.
    Anticancer Res. 2016;36:1791-7.
    PubMed     Text format     Abstract available


    March 2016
  85. KASMANN L, Janssen S, Schild SE, Rades D, et al
    Impact of the Radiation Dose on Survival after Radiochemotherapy for Small-cell Lung Cancer.
    Anticancer Res. 2016;36:1089-91.
    PubMed     Text format     Abstract available


  86. OWEN S, Gao Y, Zhi X, Wei C, et al
    Effect of YangZheng XiaoJi Extract, DME-25, on Endothelial Cells and their Response to Avastin.
    Anticancer Res. 2016;36:1181-92.
    PubMed     Text format     Abstract available


  87. SVATON M, Fiala O, Pesek M, Bortlicek Z, et al
    The Prognostic Role of KRAS Mutation in Patients with Advanced NSCLC Treated with Second- or Third-line Chemotherapy.
    Anticancer Res. 2016;36:1077-82.
    PubMed     Text format     Abstract available


  88. KATO K, Gemba K, Fujimoto N, Aoe K, et al
    Computed Tomographic Features of Malignant Peritoneal Mesothelioma.
    Anticancer Res. 2016;36:1067-72.
    PubMed     Text format     Abstract available


    February 2016
  89. JANSSEN S, Kasmann L, Rudat V, Rades D, et al
    Stereotactic Body Radiation Therapy (SBRT) for Recurrent Non-small Cell Lung Cancer (NSCLC).
    Anticancer Res. 2016;36:825-8.
    PubMed     Text format     Abstract available


  90. KASMANN L, Janssen S, Schild SE, Rades D, et al
    Karnosky Performance Score and Radiation Dose Predict Survival of Patients Re-irradiated for a Locoregional Recurrence of Small Cell Lung Cancer.
    Anticancer Res. 2016;36:803-5.
    PubMed     Text format     Abstract available


  91. YOSHIYAMA A, Morii T, Ohtsuka K, Ohnishi H, et al
    Development of Stemness in Cancer Cell Lines Resistant to the Anticancer Effects of Zoledronic Acid.
    Anticancer Res. 2016;36:625-31.
    PubMed     Text format     Abstract available


  92. KUCERA R, Topolcan O, Fiala O, Kinkorova J, et al
    The Role of TPS and TPA in the Diagnostics of Distant Metastases.
    Anticancer Res. 2016;36:773-7.
    PubMed     Text format     Abstract available


    January 2016
  93. SHI R, Diaz R, Shi Z, Duvall E, et al
    The Effect of Payer Status on Survival of Patients with Stage I/II Non-small Cell Lung Cancer: NCDB 1998-2011.
    Anticancer Res. 2016;36:319-26.
    PubMed     Text format     Abstract available


  94. KUBOTA T, Okano Y, Sakai M, Takaoka M, et al
    Carboplatin plus Weekly Paclitaxel with Bevacizumab for First-line Treatment of Non-small Cell Lung Cancer.
    Anticancer Res. 2016;36:307-12.
    PubMed     Text format     Abstract available


  95. PARK HJ, Oh JS, Chang JW, Hwang SG, et al
    Proton Irradiation Sensitizes Radioresistant Non-small Cell Lung Cancer Cells by Modulating Epidermal Growth Factor Receptor-mediated DNA Repair.
    Anticancer Res. 2016;36:205-12.
    PubMed     Text format     Abstract available


  96. LAI CY, Chang WS, Hsieh YH, Hsu CM, et al
    Association of Tissue Inhibitor of Metalloproteinase-1 Genotypes with Lung Cancer Risk in Taiwan.
    Anticancer Res. 2016;36:155-160.
    PubMed     Text format     Abstract available


  97. CHIKAISHI Y, Uramoto H, Koyanagi Y, Yamada S, et al
    TMPRSS4 Expression as a Marker of Recurrence in Patients with Lung Cancer.
    Anticancer Res. 2016;36:121-7.
    PubMed     Text format     Abstract available


  98. KIMURA Y, Sumiyoshi M, Baba K
    Antitumor and Antimetastatic Activity of Synthetic Hydroxystilbenes Through Inhibition of Lymphangiogenesis and M2 Macrophage Differentiation of Tumor-associated Macrophages.
    Anticancer Res. 2016;36:137-48.
    PubMed     Text format     Abstract available


  99. LUMACHI F, Chiara GB, Tozzoli R, Del Contea A, et al
    Factors Affecting Survival in Patients with Lung Metastases from Colorectal Cancer. A Short Meta-analysis.
    Anticancer Res. 2016;36:13-9.
    PubMed     Text format     Abstract available


  100. DEVINE A, Marignol L
    Potential of Amifostine for Chemoradiotherapy and Radiotherapy-associated Toxicity Reduction in Advanced NSCLC: A Meta-Analysis.
    Anticancer Res. 2016;36:5-12.
    PubMed     Text format     Abstract available


  101. FIALA O, Pesek M, Finek J, Svaton M, et al
    Prognostic Significance of Serum Tumor Markers in Patients with Advanced-stage NSCLC Treated with Pemetrexed-based Chemotherapy.
    Anticancer Res. 2016;36:461-6.
    PubMed     Text format     Abstract available


  102. FIALA O, Pesek M, Finek J, Minarik M, et al
    Epidermal Growth Factor Receptor Gene Amplification in Patients with Advanced-stage NSCLC.
    Anticancer Res. 2016;36:455-60.
    PubMed     Text format     Abstract available


  103. FIALA O, Pesek M, Finek J, Svaton M, et al
    Pemetrexed Versus Erlotinib in the Second-line Treatment of Patients with Advanced-stage Non-squamous NSCLC Harboring Wild-type EGFR Gene.
    Anticancer Res. 2016;36:447-53.
    PubMed     Text format     Abstract available


    December 2015
  104. SPAKS A, Jaunalksne I, Spaka I, Chudasama D, et al
    Diagnostic Value of Circulating CXC Chemokines in Non-small Cell Lung Cancer.
    Anticancer Res. 2015;35:6979-83.
    PubMed     Text format     Abstract available


  105. WATANABE S, Inoue A, Nukiwa T, Kobayashi K, et al
    Comparison of Gefitinib Versus Chemotherapy in Patients with Non-small Cell Lung Cancer with Exon 19 Deletion.
    Anticancer Res. 2015;35:6957-61.
    PubMed     Text format     Abstract available


  106. ALBERTS L, El Sharouni SY, Hofman FN, VAN Putte BP, et al
    Changes in Pulmonary Function After Stereotactic Body Radiotherapy and After Surgery for Stage I and II Non-small Cell Lung Cancer, a Description of Two Cohorts.
    Anticancer Res. 2015;35:6773-9.
    PubMed     Text format     Abstract available


    November 2015
  107. CHANG WS, Wang SC, Chuang CL, Ji HX, et al
    Contribution of Interleukin-4 Genotypes to Lung Cancer Risk in Taiwan.
    Anticancer Res. 2015;35:6297-6301.
    PubMed     Text format     Abstract available


  108. FUJIMOTO D, Shimizu R, Kato R, Sato Y, et al
    Second-line Chemotherapy for Patients with Small Cell Lung Cancer and Interstitial Lung Disease.
    Anticancer Res. 2015;35:6261-6.
    PubMed     Text format     Abstract available


  109. AGOLLI L, Valeriani M, Nicosia L, Bracci S, et al
    Stereotactic Ablative Body Radiotherapy (SABR) in Pulmonary Oligometastatic/Oligorecurrent Non-small Cell Lung Cancer Patients: A New Therapeutic Approach.
    Anticancer Res. 2015;35:6239-45.
    PubMed     Text format     Abstract available


  110. GOKE A, Goke R, Ofner A, Herbst A, et al
    The FGFR Inhibitor NVP-BGJ398 Induces NSCLC Cell Death by Activating Caspase-dependent Pathways as well as Caspase-independent Apoptosis.
    Anticancer Res. 2015;35:5873-9.
    PubMed     Text format     Abstract available


  111. YOSHIMASU T, Ohashi T, Oura S, Kokawa Y, et al
    A Theoretical Model for the Hormetic Dose-response Curve for Anticancer Agents.
    Anticancer Res. 2015;35:5851-5.
    PubMed     Text format     Abstract available


  112. DEMPKE WC, Edvardsen K, Lu S, Reinmuth N, et al
    Brain Metastases in NSCLC - are TKIs Changing the Treatment Strategy?
    Anticancer Res. 2015;35:5797-806.
    PubMed     Text format     Abstract available


  113. DEMPKE WC, Sellmann L, Fenchel K, Edvardsen K, et al
    Immunotherapies for NSCLC: Are We Cutting the Gordian Helix?
    Anticancer Res. 2015;35:5745-57.
    PubMed     Text format     Abstract available


  114. GALLO K, Brickman A, Warren WH, Gattuso P, et al
    Unresectable Middle Mediastinal Biphasic Pulmonary Blastoma.
    Anticancer Res. 2015;35:6325-7.
    PubMed     Text format     Abstract available


  115. MICHELSEN L, Sorensen JB
    Platinum-Vinorelbine Induction Chemotherapy plus Bevacizumab With and Without Pemetrexed Switch Maintenance in Advanced NSCLC.
    Anticancer Res. 2015;35:6255-9.
    PubMed     Text format     Abstract available


  116. ANDERSEN M, Trapani D, Ravn J, Sorensen JB, et al
    Methylation-associated Silencing of microRNA-126 and its Host Gene EGFL7 in Malignant Pleural Mesothelioma.
    Anticancer Res. 2015;35:6223-9.
    PubMed     Text format     Abstract available


  117. KLAIRMONT M, Kopkash K, Favuzza J, Hill M, et al
    Four Synchronous Primary Malignancies of the Breast, Lung, Colon and Esophagus.
    Anticancer Res. 2015;35:6159-62.
    PubMed     Text format     Abstract available


    October 2015
  118. AGOLLI L, Valeriani M, Bracci S, Nicosia L, et al
    Hypofractionated Image-guided Radiation Therapy (3Gy/fraction) in Patients Affected by Inoperable Advanced-stage Non-small Cell Lung Cancer After Long-term Follow-up.
    Anticancer Res. 2015;35:5693-700.
    PubMed     Text format     Abstract available


  119. HOLGERSSON G, Bergstrom S, Liv P, Nilsson J, et al
    Effect of Increased Radiotoxicity on Survival of Patients with Non-small Cell Lung Cancer Treated with Curatively Intended Radiotherapy.
    Anticancer Res. 2015;35:5491-7.
    PubMed     Text format     Abstract available


  120. NAEMURA M, Murasaki C, Inoue Y, Okamoto H, et al
    Long Noncoding RNA ANRIL Regulates Proliferation of Non-small Cell Lung Cancer and Cervical Cancer Cells.
    Anticancer Res. 2015;35:5377-82.
    PubMed     Text format     Abstract available


  121. KASTELIJN EA, El Sharouni SY, Hofman FN, Van Putte BP, et al
    Clinical Outcomes in Early-stage NSCLC Treated with Stereotactic Body Radiotherapy Versus Surgical Resection.
    Anticancer Res. 2015;35:5607-14.
    PubMed     Text format     Abstract available


  122. FRAKULLI R, Salvi F, Balestrini D, Parisi A, et al
    Stereotactic Radiotherapy in the Treatment of Lung Metastases from Bone and Soft-tissue Sarcomas.
    Anticancer Res. 2015;35:5581-6.
    PubMed     Text format     Abstract available


  123. WIEGAND S, Zimmermann A, Wilhelm T, Werner JA, et al
    Survival After Distant Metastasis in Head and Neck Cancer.
    Anticancer Res. 2015;35:5499-502.
    PubMed     Text format     Abstract available


  124. VETVICKA V, Vetvickova J
    Glucan Supplementation Has Strong Anti-melanoma Effects: Role of NK Cells.
    Anticancer Res. 2015;35:5287-92.
    PubMed     Text format     Abstract available


  125. KUNII E, Ozasa H, Oguri T, Maeno K, et al
    Reversal of c-MET-mediated Resistance to Cytotoxic Anticancer Drugs by a Novel c-MET Inhibitor TAS-115.
    Anticancer Res. 2015;35:5241-7.
    PubMed     Text format     Abstract available


  126. FERGUSON DM, Jacobson BA, Jay-Dixon J, Patel MR, et al
    Targeting Topoisomerase II Activity in NSCLC with 9-Aminoacridine Derivatives.
    Anticancer Res. 2015;35:5211-7.
    PubMed     Text format     Abstract available


    September 2015
  127. YOSHITAKE T, Shioyama Y, Asai K, Nakamura K, et al
    Impact of Interstitial Changes on Radiation Pneumonitis After Stereotactic Body Radiation Therapy for Lung Cancer.
    Anticancer Res. 2015;35:4909-13.
    PubMed     Text format     Abstract available


  128. TAWINWUNG S, Ninsontia C, Chanvorachote P
    Angiotensin II Increases Cancer Stem Cell-like Phenotype in Lung Cancer Cells.
    Anticancer Res. 2015;35:4789-97.
    PubMed     Text format     Abstract available


  129. LUANPITPONG S, Chanvorachote P
    Nitric Oxide and Aggressive Behavior of Lung Cancer Cells.
    Anticancer Res. 2015;35:4585-92.
    PubMed     Text format     Abstract available


    August 2015
  130. OTSUBO D, Yamashita K, Fujita M, Nishi M, et al
    Early-phase Treatment by Low-dose 5-Fluorouracil or Primary Tumor Resection Inhibits MDSC-mediated Lung Metastasis Formation.
    Anticancer Res. 2015;35:4425-31.
    PubMed     Text format     Abstract available


  131. TABATA A, Ohkubo Y, Anyoji N, Hojo K, et al
    Development of a Sortase A-mediated Peptide-labeled Liposome Applicable to Drug-delivery Systems.
    Anticancer Res. 2015;35:4411-7.
    PubMed     Text format     Abstract available


    July 2015
  132. ENOMOTO Y, Kenmotsu H, Watanabe N, Baba T, et al
    Efficacy and Safety of Combined Carboplatin, Paclitaxel, and Bevacizumab for Patients with Advanced Non-squamous Non-small Cell Lung Cancer with Pre-existing Interstitial Lung Disease: A Retrospective Multi-institutional Study.
    Anticancer Res. 2015;35:4259-63.
    PubMed     Text format     Abstract available


  133. BISWAS T, Walker P, Podder T, Efird JT, et al
    Effect of Race and Insurance on the Outcome of Stage I Non-small Cell Lung Cancer.
    Anticancer Res. 2015;35:4243-9.
    PubMed     Text format     Abstract available


  134. TAMIYA M, Tokunaga S, Okada H, Suzuki H, et al
    Evaluation of Bone Metastasis Using Serial Measurements of Serum N-Telopeptides of Type I Collagen in Patients with Lung Cancer: A Prospective Study.
    Anticancer Res. 2015;35:3987-93.
    PubMed     Text format     Abstract available


  135. SANDELIN M, Berglund A, Sundstrom M, Micke P, et al
    Patients with Non-small Cell Lung Cancer Analyzed for EGFR: Adherence to Guidelines, Prevalence and Outcome.
    Anticancer Res. 2015;35:3979-85.
    PubMed     Text format     Abstract available


  136. CHEN HJ, Chang WS, Hsia TC, Miao CE, et al
    Contribution of Genotype of DNA Double-strand Break Repair Gene XRCC3, Gender, and Smoking Behavior to Lung Cancer Risk in Taiwan.
    Anticancer Res. 2015;35:3893-3899.
    PubMed     Text format     Abstract available


  137. OTSUKA T, Mori M, Yano Y, Uchida J, et al
    Effectiveness of Tyrosine Kinase Inhibitors in Japanese Patients with Non-small Cell Lung Cancer Harboring Minor Epidermal Growth Factor Receptor Mutations: Results from a Multicenter Retrospective Study (HANSHIN Oncology Group 0212).
    Anticancer Res. 2015;35:3885-91.
    PubMed     Text format     Abstract available


  138. TING CY, Wang HE, Yu CC, Liu HC, et al
    Curcumin Triggers DNA Damage and Inhibits Expression of DNA Repair Proteins in Human Lung Cancer Cells.
    Anticancer Res. 2015;35:3867-73.
    PubMed     Text format     Abstract available


  139. YAN L, Nielsen FH, Sundaram S, Cao J, et al
    High-fat Diet Enhances and Plasminogen Activator Inhibitor-1 Deficiency Attenuates Bone Loss in Mice with Lewis Lung Carcinoma.
    Anticancer Res. 2015;35:3839-47.
    PubMed     Text format     Abstract available


  140. CHIARAVALLOTI A, Spanu A, Danieli R, Dore F, et al
    111In-Pentetreotide SPECT/CT in Pulmonary Carcinoid.
    Anticancer Res. 2015;35:4265-70.
    PubMed     Text format     Abstract available


  141. JANSSEN S, Schonhofer B, Rades D
    Prophylactic Radiotherapy to Intervention Sites in Malignant Pleural Mesothelioma--Single-institution Experience and Literature Review.
    Anticancer Res. 2015;35:4151-4.
    PubMed     Text format     Abstract available


  142. ZHANG Y, Zhang N, Zhao M, Hoffman RM, et al
    Real-time Non-invasive Spectral Imaging of Orthotopic Red Fluorescent Protein-expressing Lung Tumor Growth in Nude Mice.
    Anticancer Res. 2015;35:3755-9.
    PubMed     Text format     Abstract available


    June 2015
  143. KATO M, Onishi H, Furugaki K, Yunotani S, et al
    New Approach to Complete Video-assisted Thoracoscopic Lobectomy in T2 and T3 Non-Small Cell Lung Cancer.
    Anticancer Res. 2015;35:3585-9.
    PubMed     Text format     Abstract available


  144. SHIDA A, Futawatari N, Fukuyama T, Ichiki Y, et al
    Frequent High Expression of Kita-Kyushu Lung Cancer Antigen-1 (KK-LC-1) in Gastric Cancer.
    Anticancer Res. 2015;35:3575-9.
    PubMed     Text format     Abstract available


  145. LUMACHI F, Mazza F, Del Conte A, Lo Re G, et al
    Short-term Survival of Patients with Lung Metastases from Colorectal and Non-colorectal Cancer Who Underwent Pulmonary Metastasectomy.
    Anticancer Res. 2015;35:3563-6.
    PubMed     Text format     Abstract available


  146. SOCOLA F, Nguyen DM, Ochoa RE, Rocha Lima CM, et al
    A cohort study evaluating the role of surgery for lung metastases from colorectal cancer.
    Anticancer Res. 2015;35:3431-5.
    PubMed     Text format     Abstract available


  147. TANIGUCHI D, Harimoto N, Takeishi K, Itoh S, et al
    Liver transplantation followed by pulmonary resection complicated with end-stage liver cirrhosis: a case report.
    Anticancer Res. 2015;35:3411-4.
    PubMed     Text format     Abstract available


  148. GRZEGOREK I, Lenze D, Chabowski M, Janczak D, et al
    Immunohistochemical evaluation of pulmonary lymphangioleiomyomatosis.
    Anticancer Res. 2015;35:3353-60.
    PubMed     Text format     Abstract available


  149. GRZEGOREK I, Zuba-Surma E, Chabowski M, Janczak D, et al
    Characterization of cells cultured from chylous effusion from a patient with sporadic lymphangioleiomyomatosis.
    Anticancer Res. 2015;35:3341-51.
    PubMed     Text format     Abstract available


    May 2015
  150. TAKESHITA J, Masago K, Kato R, Otsuka K, et al
    A new strategy for metachronous primary lung cancer: stereotactic body radiation therapy with concurrent chemotherapy.
    Anticancer Res. 2015;35:3103-7.
    PubMed     Text format     Abstract available


  151. AZZATO EM, Deshpande C, Aikawa V, Aggarwal C, et al
    Rare Complex Mutational Profile in an ALK Inhibitor-resistant Non-small Cell Lung Cancer.
    Anticancer Res. 2015;35:3007-12.
    PubMed     Text format     Abstract available


  152. YANO Y, Otsuka T, Hirano H, Uenami T, et al
    Nuclear survivin expression in small cell lung cancer.
    Anticancer Res. 2015;35:2935-9.
    PubMed     Text format     Abstract available


  153. AUSAWASAMRIT A, Itthiwarapornkul N, Chaotham C, Sukrong S, et al
    Lupalbigenin from Derris scandens Sensitizes Detachment-induced Cell Death in Human Lung Cancer Cells.
    Anticancer Res. 2015;35:2827-34.
    PubMed     Text format     Abstract available


  154. KANG YH, Kim D, Jin EJ
    Down-regulation of Phospholipase D Stimulates Death of Lung Cancer Cells Involving Up-regulation of the Long ncRNA ANRIL.
    Anticancer Res. 2015;35:2795-803.
    PubMed     Text format     Abstract available


  155. CATTANEO F, Guerra G, Parisi M, Lucariello A, et al
    Expression of Formyl-peptide Receptors in Human Lung Carcinoma.
    Anticancer Res. 2015;35:2769-74.
    PubMed     Text format     Abstract available


  156. KO YC, Lien JC, Liu HC, Hsu SC, et al
    Demethoxycurcumin-induced DNA Damage Decreases DNA Repair-associated Protein Expression Levels in NCI-H460 Human Lung Cancer Cells.
    Anticancer Res. 2015;35:2691-8.
    PubMed     Text format     Abstract available


  157. OHASHI T, Yoshimasu T, Oura S, Kokawa Y, et al
    Class III Beta-tubulin Expression in Non-small Cell Lung Cancer: A Predictive Factor for Paclitaxel Response.
    Anticancer Res. 2015;35:2669-74.
    PubMed     Text format     Abstract available


  158. JAMY O, Yaghmour G, Hare F, Martin MG, et al
    Population-based Analysis of the Clinical Features of Primary Small Cell Carcinoma of the Ovary.
    Anticancer Res. 2015;35:3091-5.
    PubMed     Text format     Abstract available


  159. CHUDASAMA D, Rice A, Anikin V, Soppa G, et al
    Circulating Tumour Cells in Patients with Malignant Lung Tumors Undergoing Radio-frequency Ablation.
    Anticancer Res. 2015;35:2823-6.
    PubMed     Text format     Abstract available


  160. DEMPKE WC
    Targeted Therapy for NSCLC--A Double-edged Sword?
    Anticancer Res. 2015;35:2503-12.
    PubMed     Text format     Abstract available


  161. BLOMBERG C, Nilsson J, Holgersson G, Edlund P, et al
    Randomized Trials of Systemic Medically-treated Malignant Mesothelioma: A Systematic Review.
    Anticancer Res. 2015;35:2493-501.
    PubMed     Text format     Abstract available


    April 2015
  162. HONG SH, Lee JH, Jiang HL, Kim JE, et al
    Dual expression of shAkt1 and Pdcd4 suppresses lung tumorigenesis in K-rasLA1 mice.
    Anticancer Res. 2015;35:2015-9.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: